



Rhythm Biosciences

(ASX: RHY)

A Medical Diagnostics Technology Company

Mission: To reduce the impact of colorectal cancer globally through improved diagnosis

November 2018




Disclaimer

- This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.
- This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.
- This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.
- This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

Colorectal cancer is the worlds 2nd biggest cancer killer

Early Intervention Saves Lives



Regular screening is key to picking up cancers early

Addressable market of 250 million people in EU, USA & AU

Despite faecal & colonoscopy tests, **130+ million** remain totally unscreened



Blood testing has the potential to sharply increase participation

What is ColoSTAT®

Rhythm Biosciences is developing ColoSTAT for market

a simple blood test to accurately detect colorectal cancer

Blood tests are the **preferred** screening method in **over 83%** of the currently unscreened population

Over **13 years** of development at CSIRO - Australia's preeminent research organisation



ColoSTAT® Published Performance

ColoSTAT®

73% sensitivity for all colorectal cancer at **95% specificity**

58% sensitivity for early (Stage I) colorectal cancer at **95% specificity**

Fung et al. Blood-based protein biomarker panel for the detection of colorectal cancer. PLoS One (2015) 10 3.

FIT (Faecal Immunochemical Test)

65.8% sensitivity for all colorectal cancer at **94.6% specificity**

52.8% sensitivity for early (Stage I) colorectal cancer at **94.6% specificity**

Morikawa et al., Gastroenterology (2005); 129: 422-428

Key Milestones Achieved to Date


- ✓ IPO listing Dec 2017
- ✓ Strong management & board
- ✓ Strong global patent position
- ✓ Reagent development on track for 2018
- ✓ Kit development & optimisation on track for 2019
- ✓ Last two Studies (6 & 7) on track for 2019
- ✓ Ongoing CSIRO relationship remains strong
- ✓ Focus is turning to commercialisation & partnering in 2019

Key Drivers

- ✓ 250 million addressable market in screening alone
- ✓ Globally bowel cancer kills 700,000+ people pa
- ✓ 1.4 million new cases of colorectal cancer annually
- ✓ 2nd most prevalent cancer in Europe, US & Aust
- ✓ \$6bn+ global screening market alone
- ✓ \$33bn global economic burden

Strategic Objective: Replace FIT as global screening test of choice

Competitive landscape in colorectal screening



Commercial Opportunities: Government

- ✓ Objective to replace the Faecal Immunochemical Test (FIT) as global screening test of choice
- ✓ For those who don't do FIT tests (up to 50% untested)
- ✓ An additional test for FIT-positive patients to determine need for colonoscopy & reduce unnecessary/expensive colonoscopy
- ✓ Pitch to the many global governments that fund the FIT test

Commercial Opportunities: Non-Government

ColoSTAT® has the ability to be marketed across multiple channels simultaneously including:

- ✓ Global IVD/Pharma Companies
- ✓ Global Private Health Funds (redn. in unnecessary colonoscopy spend)
- ✓ Global Pathology Clinics (adapts easily to existing ELISA infrastructure)
- ✓ Global Primary Care (private clinics)

Key Milestones - 2019

- ✓ IVD kit development on track for completion in 2019
- ✓ Study 6 on track for completion in 2019
- ✓ Study 7 Clinical Trial on track for completion in 2019
- ✓ First patient to be recruited by Q1 2019 for Study 7
- ✓ ISO 13485 quality certification to be achieved in 2019
- ✓ Regulatory documentation preparation commenced for CE & TGA regulatory submissions by Q4 2019 / Q1 2020
- ✓ Bringing forward BD & Partnering Activities during 2019
- ✓ Bringing forward alternative commercial opportunities for sales
- ✓ Bring forward US clinical development program

Summary

- An addressable screening market of **250m people**
- **Multi-billion dollar** opportunity in screening alone
- Product that **costs less, simple to use & more accurate than the current faecal test**
- **Experienced board & executive team**
- **Patents** filed in key **global** jurisdictions
- Potential to **expand existing technology** into other channels
- Mission to **replace** FIT (faecal test) as global screening test of choice for bowel cancer

Thank you



RHYTHMTM
BIOSCIENCES

For more information visit
rhythmbiosciences.com